ICU Medical (NASDAQ:ICUI – Get Free Report) and Flora Growth (NASDAQ:FLGC – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.
Insider and Institutional Ownership
96.1% of ICU Medical shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 2.1% of ICU Medical shares are owned by company insiders. Comparatively, 2.3% of Flora Growth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk and Volatility
ICU Medical has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Flora Growth has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| ICU Medical | 2.15% | 7.50% | 3.91% |
| Flora Growth | -32.03% | -64.02% | -34.46% |
Earnings & Valuation
This table compares ICU Medical and Flora Growth”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ICU Medical | $2.23 billion | 1.53 | $730,000.00 | $1.85 | 73.84 |
| Flora Growth | $57.61 million | 0.09 | -$15.91 million | ($32.49) | -0.15 |
ICU Medical has higher revenue and earnings than Flora Growth. Flora Growth is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current recommendations for ICU Medical and Flora Growth, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ICU Medical | 1 | 0 | 3 | 2 | 3.00 |
| Flora Growth | 1 | 0 | 1 | 0 | 2.00 |
ICU Medical currently has a consensus price target of $168.00, indicating a potential upside of 22.98%. Flora Growth has a consensus price target of $30.00, indicating a potential upside of 522.41%. Given Flora Growth’s higher probable upside, analysts clearly believe Flora Growth is more favorable than ICU Medical.
Summary
ICU Medical beats Flora Growth on 12 of the 15 factors compared between the two stocks.
About ICU Medical
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
About Flora Growth
Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.
